Dr. Michael Gallatin brings over 35 years of experience as a scientist and executive to the Mavupharma team. He has co-founded multiple companies, including Calistoga Pharmaceuticals (acquired by Gilead Sciences), and Stromedix (acquired by Biogen Idec). Dr. Gallatin served as president of Calistoga, which was the first company to demonstrate the clinical benefit of an isoform selective PI3K (idelalisib) inhibitor in hematologic malignancies. That drug, under the brand name Zydelig, received approvals from both the FDA and EMA in 2014 to treat chronic lymphocytic leukemia and follicular lymphoma.
Previously, Dr. Gallatin was one of the founding scientists at ICOS Corporation, where he served as vice president and scientific director. His responsibilities at ICOS included discovery, preclinical research, medicinal chemistry and process chemistry groups including those that helped generate and support the worldwide registration and launch of Cialis. Earlier, he developed expertise in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center. Dr. Gallatin has also been a member of the scientific advisory boards of the Keystone Symposia, Caprion and the University of Texas Department of Chemistry. Currently, Dr. Gallatin is a senior advisor on the Frazier Healthcare Partners life sciences team, a member of the therapeutic advisory board for AnaptysBio, and a director on the board of EpiThany Inc. He is also a member of the scientific advisory board for OncoResponse and serves on the executive committee of the board of directors of the Benaroya Research Institute.
Dr. Gallatin received his Ph.D. from the University of Alberta Department of Immunology. His doctoral research focused on genetic resistance to virally induced neoplastic disease and invasive mechanisms, including the first description of antigen gain associated with organ-specific tumor metastasis. While a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the lab of Irving Weissman, Dr. Gallatin discovered the first cell adhesion molecule implicated in site selective leukocyte traffic.